Oct 06, 2020
MyoKardia Buyout: BMS expands its cardiovascular portfolio for USD 13.1 Billion Bristol Myers Squibb has bounty years in a go with its shares skyrocketing as it decides to go on an acquisition spree. BMS has announced to acquire MyoKardia, a pharmaceutical company leveraging precision medicine to ...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper